Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line

Next Previous
Trial Profile

A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribociclib (Primary) ; Anastrozole; Bevacizumab; Capecitabine; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms RIBBIT
  • Sponsors iOMEDICO AG

Most Recent Events

  • 20 Dec 2021 Status changed from active, no longer recruiting to completed.
  • 01 Dec 2021 Planned End Date changed from 30 Jun 2026 to 30 Nov 2022.
  • 25 Mar 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top